Regulus Therapeutics has concluded enrolment in the second cohort of the Phase Ib multiple ascending dose (MAD) trial of RGLS8429 to treat autosomal dominant polycystic kidney disease (ADPKD).

The placebo-controlled, double-blind study is designed to assess the pharmacokinetics, pharmacodynamics, tolerability, and safety of the miR-17 inhibitor RGLS8429 in adults with ADPKD.

It will assess treatment with RGLS8429 across three different dose levels, including measurement of changes in cyst architecture, height-adjusted total kidney volume, polycystins and overall function of the kidney.

Patients will receive 2mg/kg of RGLS8429 or placebo every other week for three months.

Regulus Therapeutics CEO Jay Hagan said: “I am looking forward to watching this cohort progress through the study as well as sharing topline data from our first cohort in the coming weeks.”

Following a review of complete available cohort 2 safety data, Regulus plans to initiate dosing the third cohort in October this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The favourable safety and PK profile of RGLS8429 were demonstrated in the Phase I single ascending dose study with no serious adverse events reported.

Plasma exposure was also found to be linear across the four tested doses and showed similar PK data as the first-generation compound, RGLS4326.

A chronic toxicity study of RGLS8429 carried out in mice for 27 weeks also demonstrated no toxicity at any dose level up to the top dose of 300mg/kg.